<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03213990</url>
  </required_header>
  <id_info>
    <org_study_id>TGI-CCT254643</org_study_id>
    <nct_id>NCT03213990</nct_id>
  </id_info>
  <brief_title>Beta-Lactam InfusioN Group Study</brief_title>
  <acronym>BLING III</acronym>
  <official_title>A Phase III Randomised Controlled Trial of Continuous Beta-lactam Infusion Compared With Intermittent Beta-lactam Dosing in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian and New Zealand Intensive Care Society Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether continuous infusion of beta-lactam
      antibiotics or intermittent infusion or beta-lactam antibiotics, offers more health
      advantages to patients or if there is no difference.

      The investigators will be looking to see whether patients receiving beta-lactams via one
      administration method or the other have a better chance of recovering from their illness.
      They will also be looking at long term outcomes such as quality-of-life and healthcare
      resource use.

      Sepsis is caused by toxic substances (toxins) from bacteria and other organism entering the
      bloodstream from a site of infection. In some people, the infection can progress to sepsis
      and septic shock where the functions of organs in the body are affected. Patients suffering
      from sepsis and septic shock are commonly managed in the intensive care unit (ICU) where they
      are prescribed antibiotics as standard therapy, as well as other therapies to support the
      functions of the body.

      Beta-lactam antibiotics are a group of antibiotics commonly used to treat infection in
      patients with sepsis and septic shock.

      Currently, beta-lactam antibiotics are most commonly given to patients be intermittent
      infusions, that is, given at regular intervals throughout 24 hours. New research suggests
      that giving beta-lactam antibiotics as a continuous infusion may mean that antibiotic
      concentrations in the blood remain more consistent and may be more effective at killing
      bacteria.

      However, the benefit to the patient by giving beta-lactams via continuous infusion has not
      been tested in a high-quality, large clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim To conduct a multicentre randomised, controlled trial (RCT) to determine whether
      continuous infusion of a beta-lactam antibiotic (piperacillin-tazobactam or meropenem)
      results in decreased all cause Day 90 mortality compared with intermittent beta-lactam
      antibiotic infusion in critically ill patients with sepsis.

      Hypothesis The BLING III Study will test the hypothesis that patients managed in the ICU with
      sepsis, the administration of beta-lactam antibiotics via continuous infusion decreases Day
      90 mortality compared with intermittent infusion Design This BLING III study is a
      prospective, multicentre, open, phase III, RCT. Participants commenced on one of two
      beta-lactam antibiotics (piperacillin-tazobactam or meropenem) will be randomised to receive
      the beta-lactam antibiotic via either continuous infusion or intermittent infusion over 30
      minutes for the treatment course while in the ICU for up to 90 days after randomisation. For
      participants where the beta-lactam antibiotic is subsequently changed from
      piperacillin-tazobactam to meropenem or vice versa for ongoing treatment of the infectious
      episode, the new prescription will continue to be administered in the allocated method
      (continuous infusion or intermittent infusion over 30 minutes).

      Permuted block randomisation with variable block sizes and stratified by site will be
      conducted via a password-protected, secure web-based interface.

      The primary endpoint for this trial will be death from all causes at 90 days.

      7,000 patients will be enrolled into this study from approximately 70 ICUs worldwide, with
      approximately 35 ICUs in Australian and New Zealand hospitals.

      For eligible patients, the administration method of beta-lactam antibiotic, either
      piperacillin-tazobactam or meropenem, will be randomised to either continuous infusion or
      intermittent infusion over 30 minutes. The choice of beta-lactam antibiotic and the dose and
      dosing interval (i.e. the dose the patient will receive in 24 hours) will be determined by
      the treating physician prior to randomisation.

      For all patients, data will be collected at baseline and daily whilst in the ICU. Patients
      will be followed up to day 14, regardless of location in the hospital, to determine test of
      cure and to identify new acquisition, colonisation or infection with an multi-resistant
      organism. Additional follow up will occur at 90 days post randomisation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 Days after randomisation</time_frame>
    <description>Patient mortality status assessed at 90 days after randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>Day 14 post randomisation</time_frame>
    <description>Clinical cure will be defined as the completion of the beta-lactam antibiotic treatment course (on or prior to Day 14) without recommencement of antibiotic therapy within 48 hours of cessation.
Participants discharged from hospital within 14 days following randomisation will be considered to meet the definition of clinical cure. Participants who decease while receiving the antibiotic treatment course or where antibiotic therapy is ceased in the setting of death being deemed imminent and inevitable, will be assessed as not meeting the criteria for clinical cure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New acquisition, colonisation or infection</measure>
    <time_frame>up to 14 days post randomisation or hospital discharge, whichever is sooner</time_frame>
    <description>New acquisition, colonisation or infection with an Multi-resistant organism (MRO) or Clostridium difficile diarrhoea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause ICU mortality</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Patient mortality status assessed at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause hospital mortality</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Patient mortality status assessed at hospital discharge</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Patient assessment of time spent in the ICU</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Patient assessment of time spent in hospital.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>90 days after randomisation</time_frame>
    <description>Quality of life measured with the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Health services use</measure>
    <time_frame>up to 90 days after randomisation</time_frame>
    <description>Cost data will be derived from health care utilisation to Day 90, estimated through standard per diem ICU and hospital costs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost effectiveness analysis</measure>
    <time_frame>up to 90 days</time_frame>
    <description>A cost-effectiveness analysis at Day 90 following randomisation will be conducted as a nested cohort in Australian sites. Cost data will be derived from health care utilisation to Day 90, estimated through standard per diem ICU and hospital costs. The analysis will be conducted from a health care payer perspective, comparing health care utilisation costs and quality-adjusted life years gained (measured by the EQ-5D-5L) between treatment arms. Where feasible, the cost-effectiveness analysis will be conducted in other country-specific regions. and quality of life between treatment arms.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7000</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Continuous Infusion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The prescribed Beta-lactam is administered by a continuous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent infusion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuous infusion</intervention_name>
    <description>Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU</description>
    <arm_group_label>Continuous Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intermittent infusion</intervention_name>
    <description>Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU</description>
    <arm_group_label>Intermittent infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented site of infection or strong suspicion of infection

          2. At the time of the assessment of suitability for the study, the treating physician
             expects the patient will require treatment in the ICU that extends beyond the next
             calendar day

          3. The treating physician has chosen piperacillin-tazobactam or meropenem to treat the
             episode of infection

          4. The treating physician is uncertain if administration of the chosen antibiotic by
             intermittent or continuous infusion is superior

          5. One or more organ dysfunction entry criteria in the previous 24 hours

               -  i. Mean arterial pressure &lt; 60 mmHg for at least 1 hour

               -  ii. Vasopressors required for &gt; 4 hours

               -  iii. Respiratory support using supplemental high flow nasal prongs, continuous
                  positive airway pressure, bilevel positive airway pressure or invasive mechanical
                  ventilation for at least 1 hour

               -  iv. Serum creatinine concentration &gt; 220 Âµmol/L

        Exclusion Criteria:

          1. Age less than 18 years

          2. Receipt of piperacillin-tazobactam or meropenem for more than 24 hours during current
             infectious episode

          3. Patients who are known or suspected to be pregnant

          4. Receiving renal replacement therapy at the time of assessment for eligibility

          5. The treating physician is not committed to provision of advanced life-support,
             including mechanical ventilation, dialysis and vasopressor administration, for at
             least the next 48 hours

          6. Death is deemed imminent and inevitable

          7. The patient has previously been enrolled in BLING III
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Lipman</last_name>
    <role>Study Chair</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorrilyn Rajbhandari</last_name>
    <phone>+61 410 530 548</phone>
    <email>drajbhandari@georgeinstitute.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Myburgh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Lipman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Peake</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 16, 2017</last_update_submitted>
  <last_update_submitted_qc>July 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Beta-lactam antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Yet to be decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

